OTB-658

OTB-658 is a novel synthetic oxazolidinone antibiotic developed as an anti-tuberculosis agent. It demonstrates potent antibacterial activity against Mycobacterium tuberculosis—including multi-drug resistant (MDR-TB) strains—both in vitro and in vivo. Mechanistically, it acts as a protein synthesis inhibitor by targeting the bacterial ribosome. Preclinical studies show that it has comparable potency to rifampicin in infected macrophage cells and exhibits lower minimum inhibitory concentrations (MICs) than linezolid against M. tuberculosis. In animal models, OTB-658 reduces bacterial counts in the lungs and inhibits growth during both acute and chronic stages of infection. The drug is orally bioavailable with an absolute bioavailability of approximately 25% at tested doses[1][2][6][7].

Other names

OTB-658OTB658OTB 658N-(((3S,3aS)-8-Fluoro-1-oxo-7-thiomorpholino-3a,4-dihydro-1H,3H-benzo[b]oxazolo[3,4-d][1,4]oxazin-3-yl)methyl)acetamide